Table 1.

Pre-treatment demographic and clinical characteristics of study participants (N=12,115).

Characteristics	Sub-group	Frequency	Percent
Sex	Females	8150	67.3
	Males	3965	32.7
Age, years	Median (IQR)	34 (29-41)
Age range, years	15-24	711	5.9
	25-45	9445	78.0
	>45	1911	15.8
	Missing data	48	0.4
Marital Status	Divorced/Separated	995	8.2
	Married	6443	53.2
	Single	2375	19.6
	Widowed	1958	16.2
	Missing data	344	2.8
Highest Education	No formal education	1993	16.5
	Primary	2473	20.4
	Secondary	3651	30.1
	Tertiary	3654	30.2
	Missing data	344	2.8
WHO disease stage	1	3964	32.7
	2	3567	29.4
	3	3085	25.5
	4	711	5.9
	Missing data	788	6.5
CD4 cell count, cell/mm3	≤100	4240	35.0
	101 – 199	3921	32.4
	200 – 349	2888	23.8
	≥350	959	7.9
	Missing data	107	0.9
	Median (IQR)	142 (72 – 230)
Viral load, copies/ml	≤10,000	3226	26.6
	10,001-100,000	4664	38.5
	>100,000	4164	34.4
	Missing data	61	0.5
	Median (IQR)	43,680 (8,475–160,213)
Hepatitis B status	Negative	8406	69.4
	Positive	2208	18.2
	Missing	1501	12.4
Tuberculosis infection	No	1388	11.5
	Yes	573	4.7
	Missing	10154	83.8